Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals has informed the exchanges that its trading window will remain closed starting 1st April, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year ended 31st March, 2026. The closure is in line with SEBI's Prohibition of Insider Trading Regulations, 2015, and applies to designated persons and their immediate relatives. The company has not yet announced the date of the board meeting where the FY26 audited results will be considered, saying it will be communicated later. This is a routine compliance intimation and signals that the Q4 and full-year FY26 results announcement is approaching.
No direct impact on shareholders. The trading window closure is a regulatory compliance step that prevents insiders from trading ahead of the upcoming audited results, which retail investors should watch for in the coming weeks.